156 related articles for article (PubMed ID: 15088933)
1. Potential therapies mimicking the effects of glucagon-like peptide-1 for the treatment of type 2 diabetes.
Rachman J
Diabet Med; 2004 Jan; 21 Suppl 1():18-20. PubMed ID: 15088933
[No Abstract] [Full Text] [Related]
2. GLP-1: target for a new class of antidiabetic agents?
Edwards CM
J R Soc Med; 2004 Jun; 97(6):270-4. PubMed ID: 15173327
[No Abstract] [Full Text] [Related]
3. Incretin mimetics as emerging treatments for type 2 diabetes.
Joy SV; Rodgers PT; Scates AC
Ann Pharmacother; 2005 Jan; 39(1):110-8. PubMed ID: 15562141
[TBL] [Abstract][Full Text] [Related]
4. [The role of incretins. Type 2 diabetes with new beginnings].
MMW Fortschr Med; 2005 Mar; 147(10):48-9. PubMed ID: 15803785
[No Abstract] [Full Text] [Related]
5. Treatment of type 2 diabetes mellitus with agonists of the GLP-1 receptor or DPP-IV inhibitors.
Holst JJ
Expert Opin Emerg Drugs; 2004 May; 9(1):155-66. PubMed ID: 15155141
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic potential of glucagon-like peptide 1 in type 2 diabetes.
Nauck M
Diabet Med; 1996 Sep; 13(9 Suppl 5):S39-43. PubMed ID: 8894470
[TBL] [Abstract][Full Text] [Related]
7. Glucagon-like peptide: a therapeutic glimmer.
Amiel SA
Lancet; 1994 Jan; 343(8888):4-5. PubMed ID: 7905051
[No Abstract] [Full Text] [Related]
8. Gut-derived incretin hormones and new therapeutic approaches.
Bloomgarden ZT
Diabetes Care; 2004 Oct; 27(10):2554-9. PubMed ID: 15451935
[No Abstract] [Full Text] [Related]
9. Proglucagon-derived peptides: mechanisms of action and therapeutic potential.
Sinclair EM; Drucker DJ
Physiology (Bethesda); 2005 Oct; 20():357-65. PubMed ID: 16174875
[TBL] [Abstract][Full Text] [Related]
10. A gut response. The next generation of type 2 drugs.
Kordella T
Diabetes Forecast; 2004 Apr; 57(4):39-42. PubMed ID: 15119299
[No Abstract] [Full Text] [Related]
11. Glucagon-like peptide 1 and gastric inhibitory polypeptide: potential applications in type 2 diabetes mellitus.
Meier JJ; Gallwitz B; Nauck MA
BioDrugs; 2003; 17(2):93-102. PubMed ID: 12641488
[TBL] [Abstract][Full Text] [Related]
12. ["Glucagon-like peptide I": a therapeutic alternative for diabetes mellitus?].
Fehmann HC; Göke B
Dtsch Med Wochenschr; 1994 Feb; 119(8):275-9. PubMed ID: 8112212
[No Abstract] [Full Text] [Related]
13. [Glucagon-like peptide-1 (GLP-1) receptor].
Taminato T
Nihon Rinsho; 2002 Jul; 60 Suppl 7():535-41. PubMed ID: 12238094
[No Abstract] [Full Text] [Related]
14. A gut feeling.
Pronsati MP
Adv Nurse Pract; 2004 Aug; 12(8):8. PubMed ID: 15354498
[No Abstract] [Full Text] [Related]
15. Glucagon-related peptide 1 (GLP-1): hormone and neurotransmitter.
Larsen PJ; Holst JJ
Regul Pept; 2005 Jun; 128(2):97-107. PubMed ID: 15780429
[TBL] [Abstract][Full Text] [Related]
16. Human studies with glucagon-like-peptide-1: potential of the gut hormone for clinical use.
Byrne MM; Göke B
Diabet Med; 1996 Oct; 13(10):854-60. PubMed ID: 8911778
[TBL] [Abstract][Full Text] [Related]
17. Pharmacology of exenatide (synthetic exendin-4): a potential therapeutic for improved glycemic control of type 2 diabetes.
Nielsen LL; Young AA; Parkes DG
Regul Pept; 2004 Feb; 117(2):77-88. PubMed ID: 14700743
[TBL] [Abstract][Full Text] [Related]
18. Gut hormones as pharmaceuticals. From enteroglucagon to GLP-1 and GLP-2.
Holst JJ
Regul Pept; 2000 Sep; 93(1-3):45-51. PubMed ID: 11033052
[No Abstract] [Full Text] [Related]
19. [A therapeutic option for type-2 diabetes. The incretion hormone GLP-1].
Göke B; Hoppe B; Konrad A; Schirra J
Pharm Unserer Zeit; 2002; 31(3):294-9. PubMed ID: 12071126
[No Abstract] [Full Text] [Related]
20. The glucagon-like peptides: a double-edged therapeutic sword?
Perry T; Greig NH
Trends Pharmacol Sci; 2003 Jul; 24(7):377-83. PubMed ID: 12871671
[No Abstract] [Full Text] [Related]
[Next] [New Search]
